PROGEN — Prostatype Genomics AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK53.98m
- SEK50.21m
- SEK0.59m
Annual cashflow statement for Prostatype Genomics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.6 | -29.1 | -41.4 | -41.1 | -44.5 |
| Non-Cash Items | 0.088 | 1.9 | 2.47 | 0.916 | 7.72 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.537 | -0.511 | 9.82 | -4.57 | 13 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -16.1 | -27.7 | -29.1 | -44.7 | -23.8 |
| Capital Expenditures | -2.5 | 0 | -8.56 | -7.86 | -13.4 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | -0.004 | -0.493 | 0.081 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -2.5 | 0 | -8.57 | -8.36 | -13.4 |
| Financing Cash Flow Items | 23.2 | 19.3 | — | — | 0.001 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23 | 18.9 | 28.9 | 59.8 | 36.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.47 | -8.84 | -8.81 | 6.74 | -0.352 |